These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 17108148)

  • 1. Germ-line genetic variation in the key androgen-regulating genes androgen receptor, cytochrome P450, and steroid-5-alpha-reductase type 2 is important for prostate cancer development.
    Lindström S; Wiklund F; Adami HO; Bälter KA; Adolfsson J; Grönberg H
    Cancer Res; 2006 Nov; 66(22):11077-83. PubMed ID: 17108148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequence variants in Toll-like receptor gene cluster (TLR6-TLR1-TLR10) and prostate cancer risk.
    Sun J; Wiklund F; Zheng SL; Chang B; Bälter K; Li L; Johansson JE; Li G; Adami HO; Liu W; Tolin A; Turner AR; Meyers DA; Isaacs WB; Xu J; Grönberg H
    J Natl Cancer Inst; 2005 Apr; 97(7):525-32. PubMed ID: 15812078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association among polymorphisms in the steroid 5alpha-reductase type II (SRD5A2) gene, prostate cancer risk, and pathologic characteristics of prostate tumors in an Ecuadorian population.
    Paz-y-Miño C; Witte T; Robles P; Llumipanta W; Díaz M; Arévalo M
    Cancer Genet Cytogenet; 2009 Mar; 189(2):71-6. PubMed ID: 19215786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer.
    Salam MT; Ursin G; Skinner EC; Dessissa T; Reichardt JK
    Urol Oncol; 2005; 23(4):246-53. PubMed ID: 16018939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estrogen receptor beta polymorphism is associated with prostate cancer risk.
    Thellenberg-Karlsson C; Lindström S; Malmer B; Wiklund F; Augustsson-Bälter K; Adami HO; Stattin P; Nilsson M; Dahlman-Wright K; Gustafsson JA; Grönberg H
    Clin Cancer Res; 2006 Mar; 12(6):1936-41. PubMed ID: 16551880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Case-control study of the genes of receptors of the androgens of vitamin-D and of 5-alphareductase in a population of Afro-Caribbean population with prostate cancer].
    Veronique-Baudin J; Dieye M; Kouyoumdjian JC; Vacheron F; Draganescu C; Azaloux H
    Prog Urol; 2006 Jun; 16(3):303-10. PubMed ID: 16821341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study.
    Hsing AW; Chen C; Chokkalingam AP; Gao YT; Dightman DA; Nguyen HT; Deng J; Cheng J; Sesterhenn IA; Mostofi FK; Stanczyk FZ; Reichardt JK
    Cancer Epidemiol Biomarkers Prev; 2001 Oct; 10(10):1077-82. PubMed ID: 11588134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The 5alpha-reductase type II A49T and V89L high-activity allelic variants are more common in men with prostate cancer compared with the general population.
    Giwercman YL; Abrahamsson PA; Giwercman A; Gadaleanu V; Ahlgren G
    Eur Urol; 2005 Oct; 48(4):679-85. PubMed ID: 16039774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphic CAG/CAA repeat length in the AIB1/SRC-3 gene and prostate cancer risk: a population-based case-control study.
    Hsing AW; Chokkalingam AP; Gao YT; Wu G; Wang X; Deng J; Cheng J; Sesterhenn IA; Mostofi FK; Chiang T; Chen YL; Stanczyk FZ; Chang C
    Cancer Epidemiol Biomarkers Prev; 2002 Apr; 11(4):337-41. PubMed ID: 11927493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic replication study of reported genetic associations in prostate cancer: Strong support for genetic variation in the androgen pathway.
    Lindström S; Zheng SL; Wiklund F; Jonsson BA; Adami HO; Bälter KA; Brookes AJ; Sun J; Chang BL; Liu W; Li G; Isaacs WB; Adolfsson J; Grönberg H; Xu J
    Prostate; 2006 Dec; 66(16):1729-43. PubMed ID: 16998812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Shorter CAG repeats in androgen receptor and non-GG genotypes in prostate-specific antigen loci are associated with decreased risk of benign prostatic hyperplasia and prostate cancer.
    Das K; Cheah PY; Lim PL; Zain YB; Stephanie FC; Zhao Y; Cheng C; Lau W
    Cancer Lett; 2008 Sep; 268(2):340-7. PubMed ID: 18495332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allelic variants of aromatase and the androgen and estrogen receptors: toward a multigenic model of prostate cancer risk.
    Modugno F; Weissfeld JL; Trump DL; Zmuda JM; Shea P; Cauley JA; Ferrell RE
    Clin Cancer Res; 2001 Oct; 7(10):3092-6. PubMed ID: 11595700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dietary intake of phytoestrogens, estrogen receptor-beta polymorphisms and the risk of prostate cancer.
    Hedelin M; Bälter KA; Chang ET; Bellocco R; Klint A; Johansson JE; Wiklund F; Thellenberg-Karlsson C; Adami HO; Grönberg H
    Prostate; 2006 Oct; 66(14):1512-20. PubMed ID: 16921512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic variation in the SST gene and its receptors in relation to circulating levels of insulin-like growth factor-I, IGFBP3, and prostate cancer risk.
    Johansson M; McKay JD; Wiklund F; Rinaldi S; Hallmans G; Bälter K; Adami HO; Grönberg H; Stattin P; Kaaks R
    Cancer Epidemiol Biomarkers Prev; 2009 May; 18(5):1644-50. PubMed ID: 19423539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of SRD5A2 sequence variants in susceptibility to hereditary and sporadic prostate cancer.
    Chang BL; Zheng SL; Isaacs SD; Turner AR; Bleecker ER; Walsh PC; Meyers DA; Isaacs WB; Xu J
    Prostate; 2003 Jun; 56(1):37-44. PubMed ID: 12746845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Genetic risk factors of prostate cancer in Han nationality population in Northern China and a preliminary study of the reason of racial difference in prevalence of prostate cancer].
    Liu JH; Li HW; Tong M; Li M; Na YQ
    Zhonghua Yi Xue Za Zhi; 2004 Mar; 84(5):364-8. PubMed ID: 15061984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic polymorphisms of hormone-related genes and prostate cancer risk in the Japanese population.
    Fukatsu T; Hirokawa Y; Araki T; Hioki T; Murata T; Suzuki H; Ichikawa T; Tsukino H; Qiu D; Katoh T; Sugimura Y; Yatani R; Shiraishi T; Watanabe M
    Anticancer Res; 2004; 24(4):2431-7. PubMed ID: 15330195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The SRD5A2 V89L polymorphism is associated with severity of disease in men with early onset prostate cancer.
    Scariano JK; Treat E; Alba F; Nelson H; Ness SA; Smith AY
    Prostate; 2008 Dec; 68(16):1798-805. PubMed ID: 18780294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. H6D polymorphism in macrophage-inhibitory cytokine-1 gene associated with prostate cancer.
    Lindmark F; Zheng SL; Wiklund F; Bensen J; Bälter KA; Chang B; Hedelin M; Clark J; Stattin P; Meyers DA; Adami HO; Isaacs W; Grönberg H; Xu J
    J Natl Cancer Inst; 2004 Aug; 96(16):1248-54. PubMed ID: 15316060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors.
    Cussenot O; Azzouzi AR; Nicolaiew N; Mangin P; Cormier L; Fournier G; Valeri A; Cancel-Tassin G
    Eur Urol; 2007 Oct; 52(4):1082-7. PubMed ID: 17448593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.